Stocktoria
ADMA BIOLOGICS, INC. ADMA
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-10-17
ADMA BIOLOGICS, INC. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M | $42.2M | — | — | $29.3M | $17.0M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M | -$19.1M | — | — | — | -$25.2M |
| R&D expense | $4.8M | $1.8M | $3.3M | $3.6M | $3.6M | $5.9M | — | — | $2.3M | $3.9M |
| SG&A expense | $91.6M | $74.1M | $59.0M | $52.5M | $42.9M | $35.1M | — | — | — | — |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M | -$64.9M | — | — | -$41.4M | -$60.3M |
| Interest expense | — | — | $25.0M | $19.3M | $13.1M | $12.0M | — | — | $9.0M | $5.5M |
| Income tax | $35.7M | -$72.0M | $0 | $0 | $0 | $0 | — | — | $0 | $0 |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M | -$71.6M | -$75.7M | $321.1M | $304.1M | -$48.3M | -$65.7M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 | $-0.88 | — | — | — | — |
| Operating cash flow | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M | -$102.0M | — | — | -$76.2M | -$62.7M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M | -$114.7M | — | — | -$80.0M | -$64.8M |
| Cash & equivalents | $87.6M | $103.1M | $51.4M | $86.5M | $51.1M | $55.9M | $59.7M | $75.8M | $26.8M | $26.8M |
| Inventory | $206.5M | $170.2M | $172.9M | $163.3M | $124.7M | $81.5M | $69.8M | $56.0M | $53.1M | $18.6M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M | $207.7M | $190.0M | $191.5M | $127.1M | $88.9M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M | $119.4M | $118.6M | $114.7M | $100.9M | $69.1M |
| Shareholders' equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M | $88.2M | $71.4M | $76.9M | $26.2M | $19.8M |
Growth · year-over-year · Revenue CAGR 62.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +19.6% | +65.2% | +67.6% | +90.4% | +91.7% | — | — | — | +72.8% | -25.4% |
| Net income growth | -25.7% | — | — | — | — | -123.6% | +5.6% | — | — | — |
| EPS growth | -25.9% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | -74.8% | +2641.3% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.